Massachusetts-based Akston Biosciences dosed the first participants in a Phase 2/3 study to test its Covid-19 vaccine, which is stable for at least six months at room temperature.
Akston Begins Trials For Room Temperature Covid Shot As Next-Generation Vaccine Race Heats Up
